Introduction
Intravenous amiodarone (iv-Amio) is one of the most widely recommended antiarrhythmic treatments for preventing the recurrence of malignant ventricular tachyarrhythmia. Cardiologists widely use it as a first-line therapy in the critical setting of malignant ventricular tachycardia (VT) or ventricular fibrillation (VF) [1] . Amiodarone has long been described as a prototype channel blocker targeting the delayed rectifier K currents (I K ), yet the effects on the I K channel are complex and remain controversial [2] . The I K currents are important determinants of cardiac repolarization and can be broadly divided into two distinctive components: a rapidly activating component (I Kr ) and slowly activating component (I Ks ) [3] . When Bosch et al. administered amiodarone to guinea pigs by intraperitoneal injection, the current densities of both I Kr and I Ks were substantially reduced in ventricular myocytes, and the levels of reduction were similar between the two components [4] . Kamiya et al., on the other hand, found that a short-term application of amiodarone brought about a significant reduction of I Kr vs only a minimal reduction of I Ks in rabbit ventricular myocytes. Kamiya's group also observed unique differential effects of amiodarone on the two I K components when they administered the drug for different durations: short-term treatment inhibited primarily I Kr , whereas long-term treatment reduced I Ks [5] . Several experimental studies have clearly shown differences in the effects of I Ks -and I Kr -blocking agents on the repolarization process (phase 2-3) [6, 7] . According to these investigations, I Ks blockers prolong the action potential duration (APD) throughout different layers or different sites of the ventricle with high uniformity without expanding the T wave or dispersion of repolarization [6, 8] . The I Kr blocker, on the other hand, preferentially prolongs cells that start out with longer APDs, and thereby elicits an increased dispersion of repolarization leading to torsade de pointes (TdP) [7, 8] . Clinical investigators, mainly from Japan, have found that the pure I Kr channel blocker nifekalant suppresses VT or VF, but it provides marked QT prolongation with an increased dispersion of repolarization, and ultimately TdP, in 3.9-17% of the patients [9, 10] . On the contrary, iv-Amio rarely induces TdP [11] . To the best of our knowledge, few studies have demonstrated why iv-Amio confers such well-balanced effects in patients with life-threatening ventricular tachyarrhythmia.
Our group hypothesized that iv-Amio inhibits both VT/VF (the conditions it targets) and proarrhythmic effect (long-QT-related TdP) by prolonging repolarization in a homogeneous and modest fashion. We tested this hypothesis by evaluating detailed electrocardiographic (ECG) changes before and during short-term amiodarone therapy, especially the dispersion of repolarization.
Methods

Study participants
We retrospectively enrolled consecutive patients with lifethreatening VT/VF in whom iv-Amio was administered continuously as a first-line antiarrhythmic therapy at our institutions between December 2009 and April 2014. To observe a purer pharmacologic action of iv-Amio, VT/VF patients who had received any class I or III drug therapy before amiodarone therapy or had failed to recover from cardiac arrest before amiodarone therapy were excluded. Patients who received continuous iv-Amio for less than 6 h were also excluded, as the ionic action and clinical efficacy of the agents were difficult to evaluate in such a short time. Patients who had received previous beta-blockers or calcium antagonists were accepted in the study, as these agents confer only minor effects on ventricular repolarization.
Clinical variables
Several clinical variables [i.e. age, gender, body mass index (BMI), underlying heart disease, left ventricular ejection fraction (LVEF), type of ventricular tachyarrhythmia (VT or VF), serum electrolytes, previous beta-blocker administration, and cumulative dose and efficacy of iv-Amio] were collected and evaluated in relation to the changes of the ECG parameters.
Administration protocol
Iv-Amio was administered according to the standard protocol, with an initial rapid infusion of 125 mg for 10 min, followed by a 6-h loading infusion of 40 mg/h, followed by maintenance infusion of 20 mg/h thereafter. In patients with low blood pressure (<100 mmHg) or very low LVEF (<25%), the treatment was sometimes commenced at the loading dose without administering an initial rapid infusion. The cumulative dose of amiodarone administered intravenously (at the time the physicians determined the efficacy of the drug) within 48 h was calculated. The protocol for this study was approved by the ethical committee of the Kinki University School of Medicine in 2014.
ECG recordings
A standard 12-lead ECG was recorded before and during iv-Amio administration. ECG recordings were obtained between 6 and 48 h after the amiodarone administration was commenced. Among the several ECG recordings taken during amiodarone therapy, we selected the recording obtained when the physicians made a decision whether the drug was effective or not. The mean interval from the initiation of amiodarone to the selected ECG recording was 21 AE 14 h.
Measurement of ECG parameters
According to evidence from several experimental studies, the cells with the shortest action potential repolarize at the peak of the T wave and the cells with the longest action potential repolarize at the end of the T wave [12, 13] . Hence, the dispersion of repolarization can be estimated by measuring the interval from the peak of the T wave to the end of the T wave (Tp-e). Here we sought to clearly determine the end of the T wave by manually measuring the following ECG parameters in all six precordial ECG leads with the amplitude of T wave !0.2 mV (Fig. 1) . The QT interval was defined as the time interval between the QRS onset and the point at which the isoelectric line intersected a tangential line visually drawn at the minimum first derivative point of the positive T wave or at the maximum point of the negative T wave. In a case with a bifurcated or secondary T wave (pathological U wave), it was included as part of the measurement of the QT interval. When, on the other hand, a normal U wave apparently separate from the T wave appeared, it was not included. The Q-T peak interval (QTp) was defined as the time interval between the QRS onset and the point at the peak of T wave. When a T wave had a biphasic or a notched configuration, the peak of the T wave was defined as that of the dominant T wave deflection. Tp-e was defined as the time interval between QTp to the end of the T wave. The QT, QTp, and Tp-e (as an index of repolarization) were corrected to the heart rate by Bazett's method (QTc; QT/HRR, c-QTp; QTp/HRR, c-Tp-e; Tp-e/HRR). The QRS duration was also measured at all leads in which QT interval parameters were obtained. The averaged QTc in the particular selected leads during amiodarone minus those before amiodarone in all patients was defined as DQTc. In three patients with atrial fibrillation, the QTc intervals following the shortest and longest R-R intervals were respectively measured and averaged (corrected by the square roots of the HRR values immediately preceding them) [14] .
To minimize the measurement error and bias, each ECG parameter was independently measured by three different skilled cardiologists without knowledge of the case status. The GrubbsSmirnovs test was used to confirm the absence of extreme values among the measurements by the three examiners before detailed analysis. Each ECG parameter was expressed as an average of three values measured independently.
Efficacy of amiodarone
A successful response to amiodarone was defined as no further VT episodes lasting more than 15 beats, no hemodynamically unstable VT/VF at any point during drug infusion therapy between 6 and 48 h, and no adverse effects requiring early termination of the drug.
Statistics
All data are presented as means AE SD. A paired t-test was used for comparisons of ECG variables (QRS interval, QTc, c-QTp, c-Tp-e, and R-R interval) between before and during administration of amiodarone, with significance assumed for p-values of 0.05 or less. Univariate logistic regression analyses were used to search for factors associated with QTc change (DQTc). The following factors were evaluated: age, gender, BMI, underlying heart disease, LVEF, type of ventricular tachyarrhythmia (VT or VF), serum K, previous beta-blocker therapy, and the cumulative dose and efficacy of amiodarone. Next, a multivariate logistic regression analysis was performed on variables with p-values of less than 0.05 in the first univariate analysis, together with several other parameters with conceivable links to QTc change.
Results
Patients
We retrospectively collected 42 consecutive patients with lifethreatening VT/VF in whom iv-Amio was administered continuously between December 2009 and April 2014 in our departments. In order to evaluate exact and purer pharmacologic action of iv-Amio, we excluded 15 VT/VF patients because of the following reasons: any class I or III drugs administered before amiodarone therapy (n = 11), no control recording of 12-lead ECG before iv-Amio (n = 2), and less than 6 h continuation of iv-Amio (n = 2). As a result, we enrolled 27 patients with life-threatening VT/VF who underwent iv-Amio administered continuously (>6 h) as a first-line antiarrhythmic therapy. Their pathologies were sustained VT or VF associated with coronary artery disease (20 patients), hypertrophic cardiomyopathy (2 patients), non-ischemic dilated cardiomyopathy (1 patient), valvular heart disease (1 patient), hypertensive heart disease (1 patient), and idiopathic VF (2 patients). The mean patient age was 71 AE 12 years and the male/female ratio was 14/13. LVEF varied from 17% to 74% and had a mean value of 42 AE 16% (Table 1) .
Efficacy and side effects of amiodarone
Amiodarone was effective in suppressing recurrence of malignant ventricular tachyarrhythmia in 19 of the 27 patients (70%, Table 1 ). None of the patients developed proarrhythmic TdP, hemodynamic deterioration, or significant liver or lung toxicities during amiodarone therapy. The total mortality rate over the 7-day period immediately following amiodarone therapy was 11% (0% in responders and 38% in non-responders). Fig. 1 illustrates ECG before and during amiodarone infusion in a case with old myocardial infarction and sustained VT (case 13). In this case, sufficient amplitude of T wave in all precordial leads except for V4 allowed us to determine the peak and the end of T wave clearly, and showed that all the parameters (QTc, c-QTp, c-Tp-e) were almost identical throughout the leads. Correspondingly, there was no apparent dispersion of QTc interval among precordial leads before and during amiodarone in all patients. Together with homogeneous QT prolongation, there was no marked T wave morphological change (i.e. degeneration to bizarre or inverted T wave) except for one patient, who exhibited a polarity inversion of the T wave during amiodarone (case 20). Therefore, we were able to utilize the same lead with the largest T wave amplitude for comparison of T wave parameters before and during amiodarone. Fig. 2 shows changes in QTc, c-QTp, and c-Tp-e intervals before and during amiodarone in selected leads from two other cases (cases 9 and 27). In panel A, apparent prolongation was observed in QTc and c-QTp (508-537 ms and 370-394 ms, respectively) without significant change in c-Tp-e (139-143 ms). In panel B, c-QTp and c-Tp-e were equally prolonged (312-334 ms and 114-134 ms, respectively), but no extreme prolongation of cTp-e was found. Overall, as shown in Figs. 3 and 4 , the QTc, c-QTp, and R-R interval were significantly prolonged during amiodarone (476 AE 45 ms vs 511 AE 45 ms, p < 0.05; 338 AE 40 ms vs 364 AE 35 ms, p < 0.05; 762 AE 272 ms vs 870 AE 189 ms, p < 0.05; respectively), whereas the c-Tp-e and QRS duration did not change significantly (139 AE 33 ms vs 145 AE 41 ms, p = 0.25; 96 AE 20 ms vs 97 AE 21 ms, p = 0.33; respectively). The mean DQTc was 35 AE 42 ms. The patient BMI was significantly related to QT interval prolongation (DQTc) in the univariate analysis [95% confidence interval (CI): À9.451 to À1.025, p = 0.017, Table 2 ]. As BMI was the only significant parameter in the univariate analysis, we performed a multivariate analysis using BMI and several other parameters that may have been linked to the DQTc, including gender and the cumulative amiodarone dose (Table 3) . BMI was recognized as an independent factor related to DQTc in the latter analysis (95% CI: À9.240 to À0.598, p = 0.027). The peak and the end of T wave are indicated by the arrows. All ECG parameters were measured in all precordial leads except for V4. QTc, c-QTp, c-Tp-e in lead V2 were prolonged (509-521 ms, 364-366 ms, and 145-155 ms, respectively) and these values are almost identical throughout the leads. QTp, QRS to T-peak; Tp-e, T-peak to T-end; repolarization indices were corrected to the heart rate by Bazett's method (QTc, cQTp, cTp-e). AMD, amiodarone; BMI, body mass index; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; HHD, hypertensive heart disease; IHD, ischemic heart disease; LVEF, left ventricular ejection fraction; R/NR, responder/non-responder; VT/VF, ventricular tachycardia/fibrillation.
ECG parameters
Fig. 2.
Repolarization parameters (QTc, c-QTp, and c-Tp-e) before and during amiodarone in selected leads from two other cases (cases 9 and 27). In panel A, apparent prolongation was observed in QTc and c-QTp (508-537 ms and 370-394 ms, respectively) without significant change in c-Tp-e (139-143 ms). In panel B, c-QTp and c-Tp-e were equally prolonged (312-334 ms and 114-134 ms, respectively), but there was no extreme prolongation in c-Tp-e. QTp, QRS to T-peak; Tp-e, T-peak to T-end; repolarization indices were corrected to the heart rate by Bazett's method (QTc, cQTp, cTp-e).
There was no significant relationship between the efficacy of amiodarone and QTc change.
Discussion
This study demonstrated one major finding: iv-Amio homogeneously prolongs repolarization and properly inhibits VT/VF recurrence without inducing TdP. Patients undergoing 12-lead ECG examinations just before amiodarone initiation were strictly selected for the study, and previous class I or III drugs were prohibited to ensure that a purer pharmacologic action of iv-Amio would be observed. To assess the electrophysiologic effect of ivAmio on the QT interval, we evaluated two distinct ECG parameters, namely, QTp and Tp-e, particularly the response of the dispersion of repolarization. QT prolongation without an accompanying increase in dispersion of repolarization suggests that iv-Amio elicits a uniformly prolonged action potential in ventricular myocytes at various sites. According to the works of Antzelevitch and colleagues [12] , the transmural dispersion of repolarization [difference between the longest APD in midmyocardial (M) cell and the shortest one in epicardial cell] contributes to the genesis of T wave, and it can be estimated by measuring Tp-e. On the contrary, Opthof et al. reported that Tp-e . QTp, QRS to T-peak; repolarization indices were corrected to the heart rate by Bazett's method (QTc, cQTp).
p=0.25 p=0.33 Fig. 4 . Comparison of the corrected T-peak to T-end (c-Tp-e) and QRS duration before and during intravenous amiodarone administration. The c-Tp-e and QRS duration did not change significantly (139 AE 33 ms vs 145 AE 41 ms, p = 0.25; 96 AE 20 ms vs 97 AE 21 ms, p = 0.33; respectively). Tp-e, T-peak to T-end; repolarization indices were corrected to the heart rate by Bazett's method (cTp-e). reflects the dispersion of repolarization time of the whole left ventricle using a canine normal heart model [13] . Although two different interpretations are being debated, both investigators commonly accepted the theory that the Tp-e represents difference between the longest APD and the shortest one in a ventricle. Therefore, measuring Tp-e is thought to be one of the best methods to evaluate the dispersion of repolarization. Several possible mechanisms may explain the optimal action of amiodarone on myocardial repolarization. First, amiodarone may potently act on the I Ks channel rather than the I Kr channel even during the brief period soon after intravenous injection. In experiments with the isolated single cell of a rabbit heart by Kamiya et al. [5] , amiodarone brought about periodically differential effects on the I K channel, namely, an I Kr current reduction in the acute phase and an I Ks current reduction in the chronic phase. Although their intriguing theory has been validated, iv-Amio may bring about different effects in a cell-to-cell coupling model or in human ventricular cells. According to several experimental studies using an arterially perfused wedge preparation by Shimizu and Antzelevitch [6] , the uniform response to I Ks blocker can be explained by the inhomogeneous gene expression of the I Ks channel in different ventricular cell types classified by APD (epicardial and M cells). More I Ks channels are present in the cells with the longer APD, which helps to explain why these have a shorter APD than other cells. Under these conditions, the same degree of I Ks inhibition in these cells presumably decreases the net repolarizing current more in the cells with a shorter APD; hence, the shorter APD can be prolonged to a greater extent. On the contrary, an agent that blocks I Kr prolongs the longer APD to a significantly greater extent and then markedly increases the dispersion of repolarization [15] , as the net repolarizing current largely depends on I Kr in the cells with the longer APD. The response of the T wave morphology and the absence of TdP after iv-Amio in the present study do not conflict with our theory that this agent has a potent I Ks -channel-blocking effect.
Second, the multi-channel-and multi-receptor-blocking behaviors of amiodarone can contribute to modest QT prolongation without increasing Tp-e. Among the various functions of amiodarone, fast sodium-channel and slow calcium-channel blocking effects may play an important role in inhibiting excessive QT prolongation [16] . In experimental studies using I Kr -channelblocking agents, mexiletine (fast sodium-channel blocker) and verapamil (L-type calcium-channel blocker) were shown to inhibit marked APD prolongation of the cells with longer APD by reducing net inward currents to a certain degree [6, 17] .
Beta-adrenergic stimulation to myocytes under a condition with strongly reduced I Ks or I Kr current elicits an inhomogeneous prolongation of APD and TdP [18] . The anti-sympathetic effects of amiodarone may preserve the modest prolongation of the QT interval. The significant R-R interval prolongation during amiodarone might partly derive from the beta-blocking effect of this agent. No association was found between previous beta-blocker therapy and DQTc, even though oral beta-blocker had been used before amiodarone in as many as 13 of the 27 patients. This can also be explained by the relatively potent beta-blocking effect of iv-Amio.
The present study also confirmed the feasibility and efficacy of iv-Amio for patients with life-threatening VT/VF. Amiodarone completely suppressed critical VT/VF in 70% of the patients in this study without producing significant side effects such as severe hypotension, TdP, or hepatic or pulmonary toxicity, regardless of their underlying heart disease.
The relationship between the efficacy of oral amiodarone and T wave response was investigated in a clinical study using a body surface mapping consisting of 87 ECG leads [19] . The rate of VT/VF recurrence was higher in the patients from the study with excessively prolonged repolarization parameters QTc interval, QT dispersion, and Tp-e. In the present study, however, we found no relationship between DQTc and the efficacy of intravenous amiodarone. This discrepant result may derive from differences in several of the clinical parameters such as the route of administration (oral vs intravenous), the underlying patient condition (stable vs emergent), and the number of ECG leads obtained (87 vs 12). Our multivariate logistic regression analysis demonstrated an association between a smaller BMI and a larger DQTc. We infused amiodarone according to a standard protocol that accounted for neither the body weight nor BMI of the patient. Under a common administration protocol, the size of an organ or fluid volume of the body may influence the drug concentration in the blood or in a targeted organ (heart). The present standard protocol is nonetheless thought to be reasonable, as we observed no significant adverse effects during the amiodarone therapy even in our patients with low BMIs. Further, a stricter protocol according to BMI would have been impracticable in emergent situations.
Clinical implications
Safety is one of the most important criteria for the selection of an antiarrhythmic drug as a first line therapy for critical cases with life-threatening ventricular tachyarrhythmia. This study has confirmed that homogeneously prolonged repolarization contributes greatly to the feasibility of iv-Amio by minimizing the risk of proarrhythmia.
Study limitations
Our study had several limitations. First, the single-arm design of this study precluded any comparison of the pharmacologic effects of iv-Amio with control or with another type of class III drug such as nifekalant (a pure I Kr blocker). A comparison of the particular responses of the QT interval using different types of class III drugs may reveal a more precise ionic mechanism of amiodarone. As mentioned earlier, a look back to previous clinical studies testing the efficacy of nifekalant would allow us to speculate on the peculiar actions of iv-Amio. Second, our evaluations of the QT interval and Tp-e were based solely on the data recorded by the one ECG lead with the largest T wave amplitude. Some investigators recommend the use of a single unipolar (precordial) lead for evaluating the transmural dispersion of repolarization and advise against averaging Tp-e among multiple leads [12, 20] . Further, as previously mentioned, our comparison of T wave parameters among all measurable precordial ECG leads revealed no significant differences (Fig. 1) . For these reasons, we are confident that the selected lead generally represents the response of the myocardium to amiodarone. Third, Bazett's formula (a method for heart rate correction of repolarization parameters) has been criticized for being inaccurate at fast heart rates. Other formulas such as the Fridericia cube-root correction and the Framingham linear regression equation are thought to be more adequate for heart rate correction of QT interval by some investigators [19] . However, none of the methods has been determined as the best method to adjust for heart rate by prospective studies. Therefore, we used Bazett's formula in the present study because this is the simplest and is widely accepted by the majority of the clinical studies.
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